TVGNW · Tevogen Bio Holdings Inc.

Tevogen Bio Holdings Inc. faces significant listing compliance challenges after receiving two separate deficiency notices from Nasdaq's Listing Qualifications Department. The company failed to meet both the $50 million minimum market value of listed securities requirement and the $15 million minimum market value of publicly held shares requirement, based on Nasdaq's review of the previous 30 consecutive business days. While the notifications have no immediate effect on the company's Nasdaq Global Market listing or trading, they trigger a critical 180-day compliance period ending in mid-October 2026. To regain compliance, the company must demonstrate sustained market value recovery, with its listed securities closing at $50 million or more and publicly held shares closing at $15 million or more for a minimum of 10 consecutive business days. The company acknowledges it may consider available options including potentially transferring to the Nasdaq Capital Market, but explicitly states there is no assurance it will be able to regain compliance or maintain listing standards. This situation creates uncertainty for investors regarding the company's continued Nasdaq listing status and may impact trading liquidity and institutional investor participation if compliance is not achieved within the specified timeframe.